- Spectrum, a small-cap biotechnology company, has five FDA-approved drugs generating revenue and a deep pipeline for hematology and oncology treatments.
- It has three drugs in the late stage of development: SPI-2012, Apaziquone and CE-Melphalan. The current market for Melphalan is worth $130 million annually.
- The upcoming catalysts for the company include NDA filing for CE-Melphalan next month, SPI-2012 Phase III go/no-go decision, and Apaziquone NDA filing by the end of this year.
- The current price level is a good entry point to go long Spectrum, as the company has sound financial conditions, approved products, prospective candidates and commercial operations.